Figure 5 — Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Research Paper|Volume 16, Issue 19|pp. 12769–12780

Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Back to articleFigure 5(5 of 7)

100%

Figure 5.Bezafibrate suppressed myocardial apoptosis after CME induction. The levels of myocardial apoptosis were assayed using the TUNEL assay (n=12, ^**, p<0.01 vs. control group; ^#, ^##, p<0.05, 0.01 vs. CME group).